DSIP - Generic Peptides

Buy DSIP by Generic Peptides at XSteroids. The letters DSIP expand to delta sleep-inducing peptide: nine amino acids, first isolated in 1974 from the blood of sleeping rabbits, and the Generic Peptides version is a lyophilized vial stocked in 2 mg and 5 mg fills. This page is deliberately blunt about the evidence: most of what is published comes from animal work and in vitro experiments, the human reports are small and partly contradictory, and no receptor for the peptide has been identified. It covers what is in the vial, the proposed mechanisms and what was actually observed.

What DSIP Is and What You Are Buying

The order contains a single glass vial of white lyophilized powder, filled at either 2 mg or 5 mg and closed under a stopper with a crimp cap. Nothing else is in the box, so bacteriostatic water, sterile water, syringes and swabs have to be bought alongside the peptide. Both fill sizes share one listing, which keeps the milligram figure on the pack option instead of the product name.

The peptide sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, written in short form as WAGGDASGE. Its formula is C35H48N10O15, its mass is near 849 g/mol, its CAS number is 62568-57-4 and its PubChem record is 68816. Both ends of the chain are blocked, which makes it an amphiphilic nonapeptide. In vitro work indicates a very short lifetime of roughly 15 minutes when a specific aminopeptidase is present, and no human half-life has been established. The name is a historical label from the 1974 experiments, not proof of a clinical effect.

How DSIP Works in Sleep Research

A peptide with no known receptor

This is the most important mechanistic fact. No gene, precursor protein or receptor has been found for DSIP, so any description of its action is a hypothesis rather than a pathway. Work on the brain suggests that some of its effects may run through NMDA receptors, and the peptide is degraded quickly by a specific aminopeptidase, which together imply a short and local mode of action. That uncertainty is unusual even among research peptides and it should inform how much weight you give to any claim about the compound.

The sleep-architecture hypothesis

The original observation was made in rabbits: when the peptide was infused into the cerebral ventricles it produced spindle and delta activity on the EEG and reduced motor activity. Later human work is where the picture blurs. Some reports describe an increase in slow-wave sleep and suppression of REM, while other studies found no reliable relationship between the peptide and sleep staging. Nothing resembling a modern polysomnographic trial with a stated primary endpoint exists.

Other axes described in the literature

Animal and in vitro reports also describe lower basal corticotropin, higher luteinizing hormone, an influence on somatostatin and growth hormone releasing hormone, anticonvulsant and antinociceptive activity, and a stress-limiting effect. These findings are scattered across decades of small experiments and none has been reproduced in a controlled modern trial.

What to Expect from DSIP Research

Expect thin data, honestly reported. The mechanistic work is animal and in vitro. The human literature is small, old and inconsistent on the peptide's headline claim about sleep. No large randomised trial has measured sleep architecture, sleep latency or subjective sleep quality after DSIP in a way that would let anyone quote an effect size.

What can be said is directional rather than numerical: in animals the peptide changed EEG patterns and reduced activity, and the short in vitro half-life suggests that any effect would be brief and tied to the timing of administration. Vendor material describes use 30 to 60 minutes before sleep with cycles of two to four weeks, but that is an administration convention rather than a finding.

One boundary worth stating clearly: DSIP is not a sedative and is not an approved treatment for insomnia anywhere. Nothing on this page should be read as a claim that it treats a sleep disorder.

Dosing DSIP for Research

Mixing a 2 mg or 5 mg vial

Everything follows from the millilitres you put in. Two millilitres into the 2 mg vial leave 1 mg in each ml, so a tenth of a millilitre carries 100 mcg, which the U-100 syringe shows at its 10-unit line; switch to 1 ml and the vial becomes twice as concentrated, putting 200 mcg under that same 10-unit mark. The 5 mg vial scales the same way: 5 ml of water gives 1 mg/ml and 100 mcg per 10 units, while 2 ml gives 2.5 mg/ml and 250 mcg per 10 units. Rotate the vial gently between the fingers instead of shaking it.

Supplier research amounts

Vendor notes describe 100 to 300 mcg subcutaneously 30 to 60 minutes before sleep, in a cycle of two to four weeks on followed by about two weeks off. At 100 mcg per day a 2 mg vial works out at roughly 20 days of material, which fits one short cycle. No published dose-finding work supports these figures; they are conventions copied around the field.

Stacking DSIP With Other Sleep and Cognitive Peptides

The closest companions in the same category are Selank, the Russian anxiolytic heptapeptide, and Semax, the ACTH-derived nootropic, with MET5 used in mood and sleep research. Longevity-oriented plans often place DSIP beside Epitalon, which is studied for circadian and pineal effects, and beside NAD+ or Glutathione for general research support. Thymalin appears in the same longevity line. None of those pairings has ever been run as a controlled combination.

Recovery and Breaks Around DSIP

There is no testosterone suppression to reverse here, because DSIP is a peptide rather than a hormone, and post-cycle therapy therefore has no place. The relevant structure is the cycle itself: supplier notes suggest two to four weeks of use with a break of about two weeks. A washout period is also the only way to compare a treated stretch with an untreated one.

DSIP Safety and Legal Status

What the evidence does not show

There is no approved DSIP product anywhere, so there is no label, no recommended dose and no pharmacovigilance record. The published human work is too small and too old to build a safety profile, and the animal literature does not answer questions about repeated exposure in people. No serious adverse event pattern is documented, but absence of documentation is not evidence of safety. Subcutaneous injections carry the ordinary local risks of redness, tenderness or swelling, and a solution that turns cloudy should be discarded.

No approved use and no anti-doping listing

The WADA Prohibited List contains no entry for DSIP, and no federation document addresses the peptide either. Silence of that kind means the data are absent, not that a permission has been granted, and the product is still an unapproved research peptide offered for laboratory work only.

Practical cautions

Because sleep problems can have medical causes, anyone with persistent insomnia, sleep apnoea symptoms or daytime impairment should seek medical assessment rather than self-experiment. Keep the product away from anyone under 18 and anyone pregnant or breastfeeding, and do not combine it with sedative medication without medical advice.

DSIP Vial Handling and Storage Rules

The sealed vial is best kept cold: 2 to 8 C in the refrigerator, away from light, and in the freezer when the gap between experiments runs into months. Once water has been added, keep the solution in the same 2 to 8 C range and use it inside 28 to 30 days, never freezing it. Allow the vial to warm to room temperature before a draw, clean the stopper with an alcohol swab, and note the volume used so the syringe reading always traces back to one documented dilution.

Why Buy DSIP from XSteroids?

Generic Peptides DSIP is stocked at XSteroids in both fill sizes, 2 mg and 5 mg, inside the Generic Peptides category among the sleep and cognition research compounds. For the anxiolytic direction see the Selank card, for the nootropic direction the Semax card, and for circadian and pineal research the Epitalon card.